Search

Recent Articles

IJMPO—A Journey of a Thousand Miles

Author : Padmaj S. Kulkarni

Coronavirus Disease 2019 Treatment—T-Cells Hold the Key in Severe Cases

Author : Kunal Das, Nitika Agrawal, Mansi Kala, Rakhee Khanduri

Why Is China Importing COVID-19 Vaccine Now?

Author : Purvish M. Parikh

Pharmacoeconomics

CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2022; 43(03): 225

DOI: DOI: 10.1055/s-0042-1750739

With the rising cost of cancer care, there is a necessity felt to address this unique demanding situation. Unique in sense, desperation and hope are playing the main role for economic expenditure by the patients in diseases where outcomes are largely limited. However, in certain diseases, immunotherapy and small molecules (tyrosine kinase inhibitors) have improved outcome that is never witnessed in the past. For example, chemotherapy combined with programmed death (PD) 1 or PD Ligand 1 inhibitors in lung cancer. This creates a situation of “between the devil and the deep blue sea” for patients when cost is beyond the reach.

Patients have been supported financially by various central and state governments, nongovernmental organizations, close relatives, and friends. In spite of this, high cost of treatment is a new cause of poverty in our country. To protect our patients and their families from financial toxicity, it is the collective social responsibility of all stake holders in cancer care including the treating doctors to protect patients from financial hardship. Academia has immense potential and has to come forward in bringing the solutions for this perpetual problem in cancer care. One of the solutions or answers is “Pharmacoeconomics.”

In this special issue of Indian Journal of Medical and Pediatric Oncology, we have worked with eminent medical oncologists from India and overseas and tried to provide few simple and easier ways of reducing the cost of cancer treatment. I hope the readers of this journal will enjoy reading this special issue and learn new approaches of cost saving.

Publication History

Article published online:
02 July 2022

© 2022. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

With the rising cost of cancer care, there is a necessity felt to address this unique demanding situation. Unique in sense, desperation and hope are playing the main role for economic expenditure by the patients in diseases where outcomes are largely limited. However, in certain diseases, immunotherapy and small molecules (tyrosine kinase inhibitors) have improved outcome that is never witnessed in the past. For example, chemotherapy combined with programmed death (PD) 1 or PD Ligand 1 inhibitors in lung cancer. This creates a situation of “between the devil and the deep blue sea” for patients when cost is beyond the reach.

Patients have been supported financially by various central and state governments, nongovernmental organizations, close relatives, and friends. In spite of this, high cost of treatment is a new cause of poverty in our country. To protect our patients and their families from financial toxicity, it is the collective social responsibility of all stake holders in cancer care including the treating doctors to protect patients from financial hardship. Academia has immense potential and has to come forward in bringing the solutions for this perpetual problem in cancer care. One of the solutions or answers is “Pharmacoeconomics.”

In this special issue of Indian Journal of Medical and Pediatric Oncology, we have worked with eminent medical oncologists from India and overseas and tried to provide few simple and easier ways of reducing the cost of cancer treatment. I hope the readers of this journal will enjoy reading this special issue and learn new approaches of cost saving.

Conflict of Interest

None declared.

Address for correspondence

Amol Patel, MD, DM
Department of Medicine, INHS ASVINI
Mumbai, Maharashtra 400005
India   

Publication History

Article published online:
02 July 2022

© 2022. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India